Ozgen Dogan, MD
Cardiovascular Disease · Brooklyn, NYNPI 1841392131
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $290,069 of the $290,425 with a category attached, or 99.9%. Abbott accounts for 99.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $56,887 and has fallen 61.5% since, to $21,875 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $949.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$290K
- Edwards Lifesciences$350
- Amgen$54
- Novartis$33
- Biotronik Inc.$33
- Amarin Pharma, Inc.$26
Across 61 payments — averaging $1865.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$114K
What the payments were for
- Consulting fees$290,069100%
- Food & beverage$3560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 299 | $289,930 |
| Edwards Lifesciences | 1 | $350 |
| Amgen | 2 | $54 |
| Novartis | 2 | $33 |
| Biotronik Inc. | 1 | $33 |
| Amarin Pharma, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE V$77,250
- Xience V coronary stent system$38,750
- PORTICO$28,750
- Mitra Clip system$25,000
- XIENCE SKYPOINT$21,875
- Portico Transcatheter Aortic Heart Valve$21,632
- Xience cornary stent systems$21,500
- Portico Transcatheter Aortic HV$15,500
- Tricuspid Valve Repair System$11,750
- ABSORB$11,000
- Absorb GT1$7,000
- MitraClip System$2,000
- Gallant CRT-D$250
- MitraClip$116
How this compares
$290,425 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $202,932 |
| EntrestoSacubitril/Valsartan | 36 | $46,559 |
| XareltoRivaroxaban | 11 | $13,677 |
| JanuviaSitagliptin Phosphate | 11 | $10,899 |
| Metoprolol Succinate | 199 | $2,939 |
| Atorvastatin Calcium | 258 | $2,910 |
| Losartan Potassium | 242 | $2,894 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 145 | $2,532 |
| Amlodipine Besylate | 387 | $2,096 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 117 | $1,726 |
| Nifedipine ErNifedipine | 43 | $1,314 |
| Terazosin Hcl | 70 | $1,215 |
| Omega-3 Acid Ethyl Esters | 16 | $1,117 |
| Simvastatin | 104 | $1,076 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $33 | $46,55936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$426K
- Warren WexelmanBrooklyn$396K
- Sergey AyzenbergBrooklyn$157K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.